Related Experiment Video
Updated: May 5, 2026
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Screening of Potential Drug Targets Based on the Genome-Scale Metabolic Network Model of Vibrio parahaemolyticus
Lingrui Zhang1, Bin Wang1, Ruiqi Zhang1
1Tianjin Key Laboratory of Animal and Plant Resistance/College of Life Sciences, Tianjin Normal University, Tianjin 300387, China.
Abstract:
Vibrio parahaemolyticus is a pathogenic bacterium widely distributed in marine environments, posing significant threats to aquatic organisms and human health. The overuse and misuse of antibiotics has led to the development of multidrug- and pan-resistant V. parahaemolyticus strains. There is an urgent need for novel antibacterial therapies with innovative mechanisms of action. In this work, a genome-scale metabolic network model (GMSN) of V. parahaemolyticus, named VPA2061, was reconstructed to predict the metabolites that can be explored as potential drug targets for eliminating V. parahaemolyticus infections. The model comprises 2061 reactions and 1812 metabolites. Through essential metabolite analysis and pathogen-host association screening with VPA2061, 10 essential metabolites critical for the survival of V. parahaemolyticus were identified, which may serve as key candidates for developing new antimicrobial strategies. Additionally, 39 structural analogs were found for these essential metabolites. The molecular docking analysis of the essential metabolites and structural analogs further investigated the potential value of these metabolites for drug design. The GSMN reconstructed in this work provides a new tool for understanding the pathogenic mechanisms of V. parahaemolyticus. Furthermore, the analysis results regarding the essential metabolites hold profound implications for the development of novel antibacterial therapies for V. parahaemolyticus-related disease.
Insights
Multidrug-resistant Vibrio parahaemolyticus poses a threat, driving the need for new treatments. Researchers developed a genome-scale metabolic network model (VPA2061) to identify essential metabolites as novel drug targets.
Area of Science:
- Microbiology
- Computational Biology
- Drug Discovery
Background:
- Vibrio parahaemolyticus is a marine bacterium causing significant health risks.
- Antibiotic resistance in V. parahaemolyticus necessitates novel therapeutic strategies.
- Genome-scale metabolic network models offer a platform for identifying drug targets.
Purpose of the Study:
- To reconstruct a genome-scale metabolic network model (VPA2061) for V. parahaemolyticus.
- To identify essential metabolites as potential drug targets for combating V. parahaemolyticus infections.
- To explore structural analogs of essential metabolites for drug design.
Main Methods:
- Reconstruction of a genome-scale metabolic network model (VPA2061) for V. parahaemolyticus.
- Essential metabolite analysis and pathogen-host association screening using VPA2061.
- Molecular docking analysis of essential metabolites and their structural analogs.
Main Results:
- The VPA2061 model includes 2061 reactions and 1812 metabolites.
- Ten essential metabolites critical for V. parahaemolyticus survival were identified.
- Thirty-nine structural analogs of these essential metabolites were identified, with potential for drug design.
Conclusions:
- The VPA2061 model serves as a valuable tool for understanding V. parahaemolyticus pathogenesis.
- Identified essential metabolites and their analogs show promise for developing new antimicrobial therapies.
- This research provides a foundation for novel antibacterial strategies against V. parahaemolyticus-related diseases.
